Patents by Inventor Chen Liaw
Chen Liaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11955425Abstract: Interconnect structures that maximize integrated circuit (IC) density and corresponding formation techniques are disclosed. An exemplary IC device includes a gate layer extending along a first direction. An interconnect structure disposed over the gate layer includes odd-numbered interconnect routing layers oriented along a second direction that is substantially perpendicular to the first direction and even-numbered interconnect routing layers oriented along a third direction that is substantially parallel to the first direction. In some implementations, a ratio of a gate pitch of the gate layer to a pitch of a first of the even-numbered interconnect routing layers to a pitch of a third of the even-numbered interconnect routing layers is 3:2:4. In some implementations, a pitch of a first of the odd-numbered interconnect routing layers to a pitch of a third of the odd-numbered interconnect routing layers to a pitch of a seventh of the odd-numbered interconnect routing layers is 1:1:2.Type: GrantFiled: February 13, 2023Date of Patent: April 9, 2024Assignee: TAIWAN SEMICONDUCOTR MANUFACTURING CO., LTD.Inventors: Fang Chen, Jhon Jhy Liaw, Min-Chang Liang
-
Publication number: 20240113097Abstract: An integrated circuit includes a first standard cell having a first pFET and a first nFET integrated, and having a first dielectric gate on a first standard cell boundary. The integrated circuit further includes a second standard cell being adjacent to the first standard cell, having a second pFET and a second nFET integrated, and having a second dielectric gate on a second standard cell boundary. The integrated circuit also includes a first filler cell configured between the first and second standard cells, and spanning from the first dielectric gate to the second dielectric gate. The first pFET and the second pFET are formed on a first continuous active region. The first nFET and the second nFET are formed on a second continuous active region.Type: ApplicationFiled: November 29, 2023Publication date: April 4, 2024Inventors: Fang Chen, Jhon Jhy Liaw
-
Patent number: 10222502Abstract: A content detection device is provided. The content detection device includes a first sensor and a controller. The first sensor is disposed near a space. The controller is coupled to the first sensor and detects a state of the first sensor. The controller performs a determination operation to determine whether an object is disposed in the space according to the detected state of the first sensor.Type: GrantFiled: May 2, 2017Date of Patent: March 5, 2019Assignee: QUANTA COMPUTER INC.Inventors: Mao-Sung Lin, Jia-Chen Liaw, Chi-Li Li, Chun-Hao Lien
-
Publication number: 20180172864Abstract: A content detection device is provided. The content detection device includes a first sensor and a controller. The first sensor is disposed near a space. The controller is coupled to the first sensor and detects a state of the first sensor. The controller performs a determination operation to determine whether an object is disposed in the space according to the detected state of the first sensor.Type: ApplicationFiled: May 2, 2017Publication date: June 21, 2018Inventors: Mao-Sung LIN, Jia-Chen LIAW, Chi-Li LI, Chun-Hao LIEN
-
Publication number: 20110177612Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: September 13, 2010Publication date: July 21, 2011Inventors: David J. Unett, Ruoping Chen, Jeremy G. Richman, Daniel Connolly, Huong T. Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin P. Lowitz
-
Publication number: 20070160987Abstract: The invention disclosed in this patent document relates to transmembrane receptors , particularly to a human G protein-coupled receptor, more particularly to a CXC chemokine receptor subtype 3 (CXCR3), and most particularly to mutated (non-endogenous) version of the human CXCR3 for evidence of constitutive activity and uses thereof. In some embodiments the altered versions of CXCR3 are used, inter alia, for the direct identification of candidate compounds such as receptor agonists, inverse agonists, partial agonist or antagonist for use in, for example and not limitation, graft rejection; inflammatory skin disease; inflammatory bowel disease; allergic inflammation, allergic pulmonary inflammation, inflammatory demyelinating neuropathy, CNS inflammation; rheumatoid arthritis, bronchiolitis obliterans syndrome, periodontal disease and neurodegenerative disease.Type: ApplicationFiled: March 15, 2004Publication date: July 12, 2007Applicant: Arena Pharmaceuticals, Inc.Inventors: Sonia Villegas, Chen Liaw
-
Publication number: 20070122878Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.Type: ApplicationFiled: May 4, 2006Publication date: May 31, 2007Inventors: Ruoping Chen, Huong Dang, Chen Liaw, I-Lin Lin
-
Publication number: 20070079392Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: November 22, 2006Publication date: April 5, 2007Applicant: Arena Pharmaceuticals, Inc.Inventors: Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Kevin Lowitz, David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly
-
Publication number: 20070072248Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.Type: ApplicationFiled: November 21, 2006Publication date: March 29, 2007Applicant: Arena Pharmaceuticals, Inc.Inventors: Ruoping Chen, Chen Liaw, Kevin Lowitz, Derek Chalmers, Dominic Behan
-
Publication number: 20060240523Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor and to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.Type: ApplicationFiled: June 30, 2006Publication date: October 26, 2006Applicant: Arena Pharmaceuticals, Inc.Inventors: Chen Liaw, Derek Chalmers, Dominic Behan, Dominique Maciejewski-Lenior, James Leonard, I-Lin Lin, Daniel Ortuno
-
Publication number: 20060183164Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is known (“known GPCRs”), and most particularly to mutated (non-endogenous) versions of the known GPCRs for use, most preferably in screening assays for the direct identification of candidate compounds as inverse agonists, agonists and partial agonists.Type: ApplicationFiled: April 14, 2006Publication date: August 17, 2006Applicant: Arena Pharmaceuticals, Inc.Inventors: Karin Lehmann-Bruinsma, Chen Liaw, I-Lin Lin
-
Publication number: 20050227295Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.Type: ApplicationFiled: November 26, 2003Publication date: October 13, 2005Inventors: Ruoping Chen, Chen Liaw, Kevin Lowitz, Derek Chalmers, Dominic Behan
-
Publication number: 20050154029Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: August 31, 2004Publication date: July 14, 2005Applicant: Arena Pharmaceuticals, Inc.Inventors: David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin Lowitz
-
Publication number: 20050119182Abstract: Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compounds. Further disclosed herein are candidate compounds identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compounds which act at the 5HT2A receptors.Type: ApplicationFiled: November 2, 2004Publication date: June 2, 2005Applicant: Arena Pharmaceuticals, Inc.Inventors: Dominic Behan, Derek Chalmers, Chen Liaw, Joseph Russo, William Thomsen
-
Publication number: 20050019840Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is known (“known GPCRs”), and most particularly to mutated (non-endogenous) versions of the known GPCRs for use, most preferably in screening assays for the direct identification of candidate compounds as inverse agonists, agonists and partial agonists.Type: ApplicationFiled: August 24, 2004Publication date: January 27, 2005Applicant: Arena Pharmaceuticals, Inc.Inventors: Karin Lehmann-Bruinsma, Chen Liaw, I-Lin Lin
-
Publication number: 20050004178Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: July 23, 2004Publication date: January 6, 2005Applicant: Arena Pharmaceuticals, Inc.Inventors: David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Kevin Lowitz
-
Publication number: 20040142377Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: December 6, 2002Publication date: July 22, 2004Applicant: Arena Pharmaceuticals, Inc.Inventors: David J. Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Huong T. Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin P. Lowitz
-
Patent number: 6485919Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.Type: GrantFiled: December 13, 1999Date of Patent: November 26, 2002Assignee: Merck & Co., Inc.Inventors: Lorrie Daggett, Steven B. Ellis, Chen Liaw, Aaron Pontsler, Edwin C. Johnson, Stephen D. Hess
-
Patent number: 6413764Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.Type: GrantFiled: September 15, 1998Date of Patent: July 2, 2002Assignee: Merck & Co., Inc.Inventors: Lorrie Daggett, Steven B. Ellis, Chen Liaw, Aaron Pontsler, Edwin C. Johnson, Stephen D. Hess
-
Patent number: 5807689Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.Type: GrantFiled: June 6, 1995Date of Patent: September 15, 1998Assignee: Sibia Neurosciences, Inc.Inventors: Lorrie Daggett, Steven B. Ellis, Chen Liaw, Aaron Pontsler, Edwin C. Johnson, Stephen D. Hess